Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$25.57M
Enterprise ValueC$17.60M
Total Cash (Recent Filing)C$4.96M
Total Debt (Recent Filing)C$316.49K
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IP & Strategic FocusLobe's dedicated R&D and IP pursuit in psychedelic-assisted therapies creates durable differentiation. Owning delivery-method and compound IP can provide barriers to entry, licensing opportunities, and a longer runway to monetize discoveries as regulatory and clinical pathways mature.
Low Near-Term LeverageModest reported debt lowers immediate solvency risk and gives management flexibility to prioritize R&D or clinical programs without large fixed financial obligations. This structural low leverage helps preserve optionality while pursuing longer-term commercialization milestones.
Evidence Of Positive Product EconomicsHistorical gross profit in periods with revenue suggests underlying product economics can be attractive. If Lobe translates R&D/IP into commercial sales, margins could scale favorably, supporting sustainable profitability once revenue growth is achieved and fixed costs are absorbed.
Bears Say
No Revenue And Persistent LossesAbsent revenue and large recurring operating losses demonstrate the company is not yet commercially viable. This structural deficit implies continued dependency on capital raises, delays path to self-sustaining operations, and increases execution risk for converting R&D into steady sales.
Negative Cash GenerationSustained negative operating and free cash flow reflects structural cash burn from R&D and operations. This necessitates external financing to fund programs, dilutes shareholder value over time, and places pressure on management to secure capital before reaching cash-flow breakeven.
Equity InstabilityEpisodes of negative equity signal historical capital shortfalls and heightened financing risk. Structural equity volatility constrains borrowing capacity and strategic flexibility, making long-term investment planning and partner negotiations more difficult until balance sheet stability is restored.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$25.57M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 34 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---